Association between rheumatoid arthritis and thyroid cancer risk: a real-world cohort study using TriNetX.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
068 patients with RA and 14 of 42,121 controls developed thyroid cancer (cumulative incidence: 0.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
• The Cox model yielded an adjusted hazard ratio of 1.40 (95% CI: 1.18-1.67), further supporting the association between rheumatoid arthritis and increased thyroid cancer risk. • Further studies are warranted to explore underlying mechanisms and guide cancer surveillance strategies in care of patients with rheumatoid arthritis.
[OBJECTIVE] To evaluate the association between rheumatoid arthritis (RA) and the risk of developing thyroid cancer using real-world data.
- p-value P < 0.001
- 95% CI 3.12-9.73
- 연구 설계 cohort study
APA
Lai SW, Kuo YH, Liao KF (2025). Association between rheumatoid arthritis and thyroid cancer risk: a real-world cohort study using TriNetX.. Clinical rheumatology, 44(11), 4495-4501. https://doi.org/10.1007/s10067-025-07668-6
MLA
Lai SW, et al.. "Association between rheumatoid arthritis and thyroid cancer risk: a real-world cohort study using TriNetX.." Clinical rheumatology, vol. 44, no. 11, 2025, pp. 4495-4501.
PMID
41021093 ↗
Abstract 한글 요약
[OBJECTIVE] To evaluate the association between rheumatoid arthritis (RA) and the risk of developing thyroid cancer using real-world data.
[METHODS] This retrospective cohort study was conducted in June 2025 using data from the TriNetX Research Network, a global federated health platform aggregating anonymized electronic medical records from 28 healthcare organizations. Patients aged 20-84 years with RA were identified and matched 1:1 to controls without RA using propensity score matching. Two time-windows were used for cancer outcome assessment: primary analysis with 1-year lag and sensitivity analysis with 180-day lag. Additionally, a Cox proportional hazards regression model was applied to estimate adjusted hazard ratio (HR), controlling for age, sex, and comorbidities.
[RESULTS] In the primary analysis (1-year lag), 77 of 42,068 patients with RA and 14 of 42,121 controls developed thyroid cancer (cumulative incidence: 0.18% vs. 0.03%; risk ratio: 5.51, 95% CI: 3.12-9.73). In the sensitivity analysis (180-day lag), the association between RA and thyroid cancer remained significant (cumulative incidence: 0.21% vs. 0.05%; risk ratio: 4.36, 95% CI: 2.68-7.08). The Cox model yielded an adjusted HR of 1.40 (95% CI: 1.18-1.67, P < 0.001), further supporting the association between RA and increased thyroid cancer risk.
[CONCLUSION] Rheumatoid arthritis is associated with a significantly elevated risk of thyroid cancer. Further studies are needed to explore underlying mechanisms and guide cancer surveillance strategies in care of patients with rheumatoid arthritis. Key Points • Patients with rheumatoid arthritis experience a significantly increased burden of cancers. • The Cox model yielded an adjusted hazard ratio of 1.40 (95% CI: 1.18-1.67), further supporting the association between rheumatoid arthritis and increased thyroid cancer risk. • Further studies are warranted to explore underlying mechanisms and guide cancer surveillance strategies in care of patients with rheumatoid arthritis.
[METHODS] This retrospective cohort study was conducted in June 2025 using data from the TriNetX Research Network, a global federated health platform aggregating anonymized electronic medical records from 28 healthcare organizations. Patients aged 20-84 years with RA were identified and matched 1:1 to controls without RA using propensity score matching. Two time-windows were used for cancer outcome assessment: primary analysis with 1-year lag and sensitivity analysis with 180-day lag. Additionally, a Cox proportional hazards regression model was applied to estimate adjusted hazard ratio (HR), controlling for age, sex, and comorbidities.
[RESULTS] In the primary analysis (1-year lag), 77 of 42,068 patients with RA and 14 of 42,121 controls developed thyroid cancer (cumulative incidence: 0.18% vs. 0.03%; risk ratio: 5.51, 95% CI: 3.12-9.73). In the sensitivity analysis (180-day lag), the association between RA and thyroid cancer remained significant (cumulative incidence: 0.21% vs. 0.05%; risk ratio: 4.36, 95% CI: 2.68-7.08). The Cox model yielded an adjusted HR of 1.40 (95% CI: 1.18-1.67, P < 0.001), further supporting the association between RA and increased thyroid cancer risk.
[CONCLUSION] Rheumatoid arthritis is associated with a significantly elevated risk of thyroid cancer. Further studies are needed to explore underlying mechanisms and guide cancer surveillance strategies in care of patients with rheumatoid arthritis. Key Points • Patients with rheumatoid arthritis experience a significantly increased burden of cancers. • The Cox model yielded an adjusted hazard ratio of 1.40 (95% CI: 1.18-1.67), further supporting the association between rheumatoid arthritis and increased thyroid cancer risk. • Further studies are warranted to explore underlying mechanisms and guide cancer surveillance strategies in care of patients with rheumatoid arthritis.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Lipid‑Lowering Agents and Hepatocellular Carcinoma Risk.
- Comment on "Lower glycemic status was associated with pancreatic cancer risk in prediabetes".
- Pancreatitis, Type 2 Diabetes Mellitus, and Pancreatic Cancer (Diabetes Metab J 2025;49:252-63).
- Antrocinol-mediated downregulation of ATG5 induces autophagy-dependent cell death and activates the unfolded protein response through PERK/CHOP signaling in lenvatinib-resistant hepatocellular carcinoma cells.
- New-onset diabetes mellitus and the risk of pancreatic cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- CHI3L1 Is Associated With TP53 Signaling and Promotes Papillary Thyroid Carcinoma Progression.
- Obesity-driven thyroid cancer burden in middle-aged and older populations: temporal trends and projected trajectories based on the Global Burden of Disease study.
- Impact of health information prescription in thyroid cancer.
- Visualizing malignant progression: in situ CD109-based spatial immunofluorescence assay delineates papillary to anaplastic thyroid carcinoma transformation within the tumor microenvironment.